IN the perioperative period, anaphylactic reactions are often induced by the intravenous administration of muscle relaxants, antibiotics, colloids, and radiocontrast materials as well as after local contact with latex-containing materials (e.g., gloves, catheters, airway tube) and chlorhexidine.\(^1\) Inhalation of toxic and highly irritant substances contained in cleaning solutions has occasionally been incriminated to produce acute bronchospasm and hypersensitization to other allergens.\(^2\) In this report, the postoperative onset of bronchospasm, hypotension, and urticaria is described and the involvement of both immune and nonimmune mechanisms is discussed.\(^3\)\(^4\)

### Case Report

A 43-yr-old female nurse was referred to our hospital for open resection of a 15-mm pulmonary nodule located in the right lower lobe. She had stopped smoking 4 yr previously, and her past medical history included mild urticarial reaction to penicillin, erythromycin, codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.

On the day of surgery, the patient was premedicated with 7.5 mg midazolam orally, a thoracic epidural catheter was placed, and 1.5 g codeine, and aspirin. Over the previous 6 months, the use of a disinfectant compound (Synergen®; Democal AG, Villars-sur-Glâne, Switzerland) at her workplace typically produced recurrent episodes of dry cough, breathlessness, and chest tightness. Otherwise, her medical examination, laboratory results, and functional lung volumes were all within normal values.
anaphylaxis before the correct agent is clearly identified. Sensitized patients often have multiple episodes of anaphylaxis before the correct agent is clearly identified. Hospital workers are regularly exposed to latex-containing products and toxic substances (e.g., disinfectant) that may be implicated in various allergic and irritative reactions. Recently, life-threatening anaphylactic reactions to chlorhexidine have also been described, particularly among patients requiring repeated invasive procedures.

In our patient, mild signs of contact dermatitis had been overlooked at the preoperative consultation and a perioperative latex-free environment was not deemed necessary. After surgery, the diagnosis of latex hypersensitivity was clearly documented by immunologic testing, although no acute symptom was elicited by direct contact with the face mask, oral airway, bronchial tube, ventilation circuit, urinary catheter, perfusion lines, or surgical gloves, which all contained latex.

A striking clinical feature was the close temporal association between a routine cleaning procedure near the extubated patient and the onset of life-threatening manifestations. Although immune hypersensitization to several reactive chemicals contained in surface disinfectant has been reported in anecdotal clinical cases, allergologic investigations were all negative for intravenous drugs, surface disinfectants (including chlorhexidine), and cleaning substances, except for latex.

Several arguments suggest that inhalation of sprayed forms of disinfectant products could trigger the observed sequence of respiratory, cardiovascular, and cutaneous abnormalities. First, clinical history confirmed the hyperreactivity of the patient’s airway to the same disinfectant, characterized by dry cough and dyspnea; high airway concentrations of water-soluble substances like quaternary amines (didecyl-dimethyl-ammonium-chloride) contained in most disinfectants are known to induce reversible upper airways constriction in susceptible subjects, a so-called reactive airway dysfunction syndrome. Second, chronic or repeated exposure to nonallergenic and irritant substances included in disinfectants has been shown to enhance IgE sensitization to common allergens (e.g., latex) and has been identified as a risk factor for atopy and airway constriction. Third, didecyl-dimethyl-ammonium-chloride is a polycationic agent whose interaction with membrane surface receptors has been shown to potentiate the release of IgE-dependent histamine from mastocytes and therefore to amplify the acute response to immunogenic agents. Fourth, the release of inflammatory mediators (e.g., cytokines, prostanoids) as a result of surgical manipulation, ischemia-reperfusion injury, and stress failure of the alveolar-capillary barrier could also amplify the anaphylactic response and its clinical manifestations.

Taken together, these data suggest that “silent” hypersensitivity to latex could possibly be aggravated or unmasked by concomitant airway challenge with quaternary amines acting as coallergens in the context of surgical stress, airway instrumentation, and one-lung ventilation. Although intraoperative exposure to multiple latex-containing products failed to provoke an immediate allergic reaction, inhalation of disinfectant substances shortly after tracheal extubation was associated with the development of the full scale of acute respiratory, hemodynamic, and cutaneous manifestations.
CASE REPORTS

Latex Anaphylaxis after Tourniquet Release during Total Knee Arthroplasty

Philippe Pirat, M.D.,* Sandrine Lopez, M.D.,* Frédéric Motais, M.D.,* Marie-Caroline Bonnet, M.D.,* Xavier Capdevila, M.D., Ph.D.†

THE risk of an anaphylactoid reaction represents 9–19% of all complications associated with anesthesia, and the rate of all perioperative deaths due to anaphylactic shock has been estimated at 5–7%. In France, 16.5% of anaphylactoid reactions during anesthesia involve hypersensitivity to latex,1 and cases of perioperative shock have been attributed to this allergen.3–5 To the best of our knowledge, there are no previous case reports of latex anaphylaxis after tourniquet release during orthopedic surgery. Our report involves a patient who developed severe anaphylactic shock when the tourniquet was deflated after knee arthroplasty. The patient’s outcome was favorable.

Case Report

A 65-year-old woman with a history of asthma was scheduled for total knee arthroplasty. The preoperative interview revealed no allergy to medications. However, the patient described an incident of severe anaphylactic shock when the tourniquet was deflated after knee arthroplasty. The patient’s outcome was favorable.

References


© 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.
The anaphylactic nature of the shock was confirmed by analysis of the perioperative samples, which showed an increase in plasma concentrations of tryptase (immunoenzymatic dosage, UniCAP Tryptase System; Pharmacia, Paris, France) and histamine (RIA Histamine®; Immunootech, Paris, France). The tryptase concentration was 26.4 μg/l (normal value, < 12 μg/l), and the histamine concentration was 68.2 nm (normal value, < 9 nm). Latex-specific immunoglobulin E (immunoenzymatic dosage, CAP Fluorescence System®; Pharmacia) was 2.39 kU/l (normal value, < 0.35 kU/l; class 2; moderate).

At a follow-up visit 6 weeks later, the patient reported an episode of edema of the lips after eating an avocado several years earlier. Interview found no occupational exposure to latex and no history of anaphylactoid reaction to domestic products containing latex.

The patient did not react to a prick test with 0.4% phenol in saline (negative control) but had a wheal of 6 mm with a prick test with 9% codeine phosphate (positive control). Prick tests with latex were performed using two different commercial fresh natural rubber latex extracts (Stallergene® Stallergenes Laboratories, Antony, France) and Allerbio® (AB Laboratories, Varennes-en-Argonne, France). Both extracts yielded a positive reaction. After 15 min, Stallergene® yielded a wheel of 8 mm, and Allerbio® yielded a wheel of 5 mm. A second test for latex-specific immunoglobulin E was performed, showing a high specific immunoglobulin E concentration of 12.4 kU/l (class 3). To reinforce the suspected diagnosis, an in vitro study of basophil degranulation was also performed. This method uses flow cytometry to quantify the amount of CD63 induced by various antigens.6 The value of basophil degranulation was 16% for latex with 1 μl Stallergene® solution and 17% for latex with 10 μl Stallergene® solution. This value was 26% for avocado with 10 μl Stallergene® solution. No degranulation was induced by a kiwi antigen. No reaction was observed during antigenic stimulation with dust mites or grass seeds. Intradermal tests were performed with the other anesthetics used for the patient, but results of these tests were negative.

Discussion

Despite that the release of metabolically active products and mediators from the acutely ischemic leg and acute loss of volume may have contributed to hypotension, the diagnosis of anaphylactic shock reaction to latex on removal of the tourniquet was quite likely. It was based on substantial clinical and biologic evidence, including positive results of skin tests. A female predominance of anaphylactic shock during anesthesia has been reported.7 The patient’s history of fruit allergy and atopic disease should be emphasized.8,9 When the limb was revascularized, systemic dispersal of the putative antigen was immediately followed by a severe allergic reaction (grade III) in this patient. She may have developed sensitivity to latex during previous surgical or occupational exposure. This has already been demonstrated for children10 and adults.11 An anaphylactic reaction has been estimated to occur in one third of all patients who have a known allergy to latex.12 Theoriginality of the current case lies in the onset by cardiovascular collapse after tourniquet release.

Very similar events have been described on release of a tourniquet after applying rifamycins to an operative wound in patients who had previously been sensitized to rifamycins.13,14 In these observations, shock occurred 10 min after tourniquet release. Although the delay was shorter in the current case, the clinical picture was comparable. In the cases involving rifamycin, contact between the allergen and the operative site was extensive. In our case, surgical contact primarily consisted of contact with surgical instruments. There was brief contact with the surgeon’s gloves during use of the trial prosthesis and application of cement. Consequently, the embolization of very few particles of latex after removal of the tourniquet was apparently sufficient to trigger the anaphylactic reaction. The same type of mechanism has been hypothesized in cases of obstetric patients who received oxytocin infusions subsequent to endouterine contact with latex gloves.7,15–17 The allergen was thought to have been abruptly forced into the circulation by the induced uterine contractions leading to the immunoglobulin E-dependent reaction.

The current case report illustrates the usefulness of a thorough preanesthesia interview with an exhaustive list of all foods documented to have cross-allergies with latex (including avocado, banana, kiwi, pineapple, passion fruit, etc).6,18,19 Despite the absence of glove-related skin symptoms in our patient, the cross-reactivity between latex and avocado is obvious.20,21 Recent studies have reported hevein-like protein domains responsible for major cross-reacting allergen reactions with avocado.22,23 Including a list of such food allergens in the preanesthesia questionnaire is recommended.1 Findings of this interview would permit efficient scheduling of an allergy workup adapted to the anticipated surgical procedure, possibly reducing the number of perioperative anaphylactic incidents. This report also provides support for the policy of immediately clearing an operative wound of latex in cases of anaphylactic shock to an agent that has not been clearly identified.

References

Use of Inhaled Iloprost in a Case of Pulmonary Hypertension during Pediatric Congenital Heart Surgery

Matthias Müller, M.D.,* Stefhan Scholz, M.D.,* Myron Kwapisz, M.D.,† Hakan Akintürk, M.D.,‡ Josef Thul, M.D.,§ Gunter Hempelmann, M.D.||

Case Report

A 6-month-old infant girl, weighing 3.66 kg, was scheduled for atrial and ventricular septal closure. The preoperative medical history included gestational age of 29 weeks at birth, trisomy 21, and bronchopulmonary dysplasia. Preoperative cardiac catheterization revealed an unrestrictive ostium secundum type atrial septum defect and an unrestrictive perimembranous ventricular septal defect, resulting in pulmonary hypertension with a pulmonary-to-systemic perfusion ratio (Qp/Qs) of 1.4 and a pulmonary-to-systemic vascular resistance ratio (Rp/Rs) of 0.6. The preanesthetic medication consisted of aldactone, hydrochlorothiazide, digoxin, and antibiotics. In the operating room, general anesthesia was induced with fentanyl followed by pancuronium bromide and was maintained with fentanyl (total dose, 82 \( \mu \)g/kg), isoflurane (maximum end-tidal concentration 0.4 vol%), and midazolam (total dose, 0.4 mg/kg) after starting CPB. CPB was performed using nonpulsatile flow (2.4 l/min \( \times \) m\(^2\)) with a membrane oxygenator in moderate hypothermia (rectal temperature > 35°C). To maintain full CPB flow at acceptable systemic pressures, the \( \alpha \)-adrenergic antagonist urapidil (total dose, 1.0 mg/kg) was administered to keep the mean systemic blood pressure below 40 mmHg. Cold crystalloid cardioplegia (Breitschneider [histidine tryptophane ketoglutarate] solution, 110 ml) was given before clamping the aorta. The aortic clamping time was 65 min. During weaning from CPB, aortic flow was effective at the first attempt. Inhaled iloprost (2.5 \( \mu \)g/kg \( \times \) over 20 min) was administered after weaning off CPB, because the mean pulmonary artery pressure/mean systemic blood pressure ratio (Pp/Ps) was increased to 0.72 and arterial oxygen saturation was 76%, despite hyperventilation (\( \text{PaCO}_2, 30–35 \) mmHg) with an inspired oxygen fraction of 1.0. Iloprost was prepared from a vial of Ilomedin 50 i.v. (Schering AG, Berlin, Germany) containing iloprost 50 \( \mu \)g i.v.

IMPAIRED endothelium-dependent vasodilatation is present in children with high pulmonary flow and pressure which might be exacerbated by cardiopulmonary bypass (CPB).\(^{1,2} \) It has been reported that an increased pulmonary vascular resistance, either directly or as a surrogate of the systemic inflammatory response after cardiopulmonary bypass, has a significant effect on the postoperative recovery of infants after cardiac operations.\(^{3} \) Iloprost is the stable carbacyclin derivative of prostaglandin I\(_2\). The use of aerosolized prostaglandin I\(_2\) has shown to be safe in healthy lambs with regard to coagulation parameters, hemodynamics, and pulmonary toxicity.\(^{4,5} \) Inhaled iloprost has been used as a diagnostic tool to assess the vasodilator capacity of the pulmonary vascular bed in children with congenital heart disease and elevated pulmonary vascular resistance, as well as intensive care unit treatment of pulmonary hypertension in a small series of children after cardiac surgery.\(^{6} \) In adults, inhaled iloprost has been successfully used to control pulmonary hypertension after CPB.\(^{7} \) However, no data are available about the intraoperative use of inhaled iloprost in infants younger than 1 yr with pulmonary hypertension undergoing cardiac surgery.

---

* Consultant, † Resident, Department of Anaesthesiology, Intensive Care Medicine, Pain Therapy, ‡ Consultant, Department of Cardiac and Pediatric Cardiac Surgery, § Consultant, Department of Pediatric Cardiology, and ¶ Professor and Chairman, Department of Anaesthesiology, Intensive Care Medicine, Pain Therapy, University Hospital Giessen.

Received from the Department of Anaesthesiology, Intensive Care Medicine, Pain Therapy, University Hospital Giessen, Giessen, Germany. Submitted for publication December 13, 2002. Accepted for publication March 11, 2003. Support was provided solely from departmental sources.

Address reprint requests to Dr. med. Muller: Department of Anaesthesiology, Intensive Care Medicine, Pain Therapy, University Hospital Giessen, Rudolf-Buchheim-Str. 7, 35392 Giessen, Germany. Address electronic mail to: Matthias.Mueller@chiru.med.uni-giessen.de. Individual article reprints may be purchased through the Journal Web site, www.anesthesiology.org.
The effects of iNO vary among patients and cum-

lent with 100% oxygen. In accordance with Ri-
dose of inhaled iloprost is not very effective in infants
or a minor response to iNO. Inhaled
mental ventilation in the pediatric intensive care unit. The patient was ventilated for 6
postoperative days and was discharged to the referring hospital on the
seventh postoperative day.

Discussion

This case report demonstrates that a single dose of
inhaled iloprost ($2.5 \mu g \times kg^{-1}$ over 20 min) may be
used to decrease Pp/Ps and to improve oxygen satu-
ration in an infant after weaning off CPB; 120 min later the
Pp/Ps returned to baseline. A documented hemody-
namic effect for 1 to 2 h has previously been described.8
The effective dose of inhaled iloprost in infants is not
clear and seems to be dependent on the clinical setting.
From previous applications, we speculate that a lower
dose of inhaled iloprost is not very effective in infants
after weaning off CPB, who were already hyperventi-
lated with 100% oxygen. In accordance with Ri-
mensberger et al.,6 we observed no decrease in systemic
blood pressure even though we used a fivefold higher
dose. This may be explained by our clinical setting (i.e.,
immediately after weaning off CPB; intraoperative use of
the systemic vasodilators rapidil and milrinone).
Theoretically, different characteristics of the aerosol spray
may result in different intrapulmonary drug depletion
characteristics, which could explain the lack of spillover
into systemic circulation. However, we used a tested
ultrasonic nebulizer (Optineb®; Nebu-Tec, Eisenfeld,
Germany) that provided an aerosol with a mass median
aerodynamic diameter of the droplets of 3.4 \mu m.

Although iNO is widely used to decrease pulmonary
vascular resistance in infants undergoing cardiac sur-
gery, the effects of iNO vary among patients and cum-
bersome devices are necessary to administer iNO safe-
ly.9,10 Furthermore, rebound phenomena have been
described with iNO withdrawal, bearing the risk of life-
threatening pulmonary hypertensive crisis (e.g., during
transportation to the intensive care unit).11 Inhaled
iloprost may, therefore, be an alternative for selective pul-
monary vasodilation in infants undergoing cardiac surgery
because it is effective, easy to use, and long-acting. Furth-
more, from an economic point of view inhaled iloprost
may be attractive because iNO became very expensive
after approval by the Food and Drug Administration.

References

1. Celermajer DS, Cullen S, Deanfield JE: Impairment of endothelium-depen-
dent pulmonary artery relaxation in children with congenital heart disease and
abnormal pulmonary hemodynamics. Circulation 1993; 87: 440–6
oxide and acetylene in the evaluation of pulmonary hypertension and endo-
thelial function after cardiopulmonary bypass. Circulation 1993; 88: 2128–38
3. Schulze-Neick I, Li J, Penny DJ, Redington AN: Pulmonary vascular resis-
tance after cardiopulmonary bypass in infants: Effect on postoperative recovery.
J Thorac Cardiovasc Surg 2001; 121: 1053–9
Messmer K: Eight hours’ inhalation of prostacyclin (PGI2) in healthy lambs:
Effects on tracheal, bronchial, and alveolar morphology. Intensive Care Med
1996; 22: 1232–8
B, Krombach F, Messmer K: Inhalation of prostacyclin (PGI2) for 8 hours does
not produce signs of acute pulmonary toxicity in healthy lambs. Intensive Care
6. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli
B, Beghetti M: Inhaled nitric oxide versus aerosolized iloprost in secondary
pulmonary hypertension in children with congenital heart disease: Vasodilator
capacity and cellular mechanisms. Circulation 2001; 103: 544–8
Antoniou T: Inhaled iloprost controls pulmonary hypertension after cardiopul-
8. Hoeger MM, Olschewski H, Ghojiani HA, Wilkens H, Winkler J, Bors E,
Niedermeyer J, Fabel H, Seeger W: Comparison of the acute hemodynamic
effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary
Semin Perinatol 1997; 21: 441–55
GJ, Davis KJ, Hyers TM, Papadakos P: Effects of inhaled nitric oxide in patients
with acute respiratory distress syndrome: Results of a randomized phase II trial.
11. Aitz AM, Adatia I, Wessel DL: Rebound pulmonary hypertension after

Table 1. Changes in Hemodynamic Parameters and Arterial Oxygen Saturation

<table>
<thead>
<tr>
<th></th>
<th>Before II</th>
<th>End of II</th>
<th>60 min after II</th>
<th>120 min after II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate, beats/min</td>
<td>137</td>
<td>143</td>
<td>142</td>
<td>162</td>
</tr>
<tr>
<td>Systemic blood pressure, mmHg</td>
<td>73/58/45</td>
<td>73/54/41</td>
<td>72/54/42</td>
<td>62/43/35</td>
</tr>
<tr>
<td>Pulmonary artery pressure, mmHg</td>
<td>59/42/28</td>
<td>46/34/25</td>
<td>43/32/22</td>
<td>47/35/26</td>
</tr>
<tr>
<td>Pp/Ps</td>
<td>0.72</td>
<td>0.63</td>
<td>0.59</td>
<td>0.81</td>
</tr>
<tr>
<td>Arterial oxygen saturation, %</td>
<td>76</td>
<td>90</td>
<td>90</td>
<td>89</td>
</tr>
</tbody>
</table>

II = inhaled iloprost; Pp/Ps = mean pulmonary artery pressure/mean systemic blood pressure ratio.
Intraoperative Management of Severe Pulmonary Hypertension during Cardiac Surgery with Inhaled Iloprost

Steffen Rex, M.D., * Thomas Busch, M.D., † Manfred Vettelschoss, M.D., ‡ Lothar de Rossi, M.D., § Rolf Rossaint, M.D., ¶ Wolfgang Buhre, M.D., §§

PULMONARY hypertension is an important risk factor for the development of acute right heart failure after cardiac surgery. 1,2 Even with early and adequate therapy, right ventricular (RV) failure is associated with increased morbidity and mortality. 1,3 We report the case of a patient with severe pulmonary hypertension related to aortic valve stenosis and mitral valve insufficiency who underwent combined bivalvular surgery and coronary artery bypass grafting. Pulmonary vascular resistance (PVR) was effectively decreased after the administration of inhaled iloprost before cardiopulmonary bypass (CPB) and during weaning from CPB. RV failure could be avoided and the perioperative course was uneventful.

Case Report

A 78-yr-old female patient (height, 1.75 m; weight, 74 kg) presented with a history of syncope and congestive heart failure. Cardiac catheterization revealed severe aortic valve stenosis (aortic valve area, 0.49 cm²; mean pressure gradient 58 mmHg), mitral valve insufficiency (degree II), critical stenosis of the left main coronary artery, impaired left ventricular function, and hypokinesia of the anterior and apical left inferior wall. Furthermore, severe pulmonary hypertension was diagnosed (pulmonary artery pressure, 80/30 mmHg; mean pulmonary artery pressure, 65 mmHg; pulmonary artery occlusion pressure, 45 mmHg).

After the induction of anesthesia with sufentanil and midazolam, anesthesia was maintained with isoflurane and sufentanil. Hemodynamic monitoring consisted of arterial, central venous, and pulmonary artery catheterization. Hemodynamic parameters are presented in table 1. In addition, transesophageal echocardiography (Omniplane II T6210 probe; Sonos 5500, Philips Medical Systems, Best, The Netherlands) was performed intraoperatively. Before CPB, transesophageal echocardiography confirmed the diagnoses obtained by cardiac catheterization and revealed severe RV dysfunction. Detailed echocardiographic data are listed in table 2.

After the induction of anesthesia, nitroglycerin was administered intravenously to decrease PVR; however, the nitroglycerin was not effective (table 1). After sternotomy, PVR increased, probably because of increased RV preload caused by the reduction in intrathoracic pressure. Therefore, we administered 12.5 µg aerosolized iloprost (Ilomedin®; Schering Deutschland GmbH, Berlin, Germany) over 15 min via a commercially available nebulizer (Aeroneb®; Pro: Aerogen Inc., Mountain View, CA) connected to the inspiratory limb of the ventilator circuit. The administration of iloprost significantly decreased pulmonary artery pressure and PVR and was accompanied by an increase in cardiac output. CPB was performed using moderate hypothermia (30°C), and cardiopulmonary arrest was instituted with 2 l of crystalloid cardioplegia. The patient underwent aortic valve replacement, mitral valve repair, and aorto-coronary bypass grafting to the left anterior descending and circumflex arteries. The duration of ischemia was 140 min. After 80 min of reperfusion, 12.5 µg inhaled iloprost were again administered over 15 min. Weaning from CPB was completed after a reperfusion time of 97 min. Moderate doses of vasoactive agents were administered to achieve adequate hemodynamic parameters. Transesophageal echocardiography showed an improvement in RV-function parameters after CPB: the RV-fractional area change increased from 18% (pre-CPB) to 38% (post-CPB). The patient was transferred to the intensive care unit, and endotracheal extubation was performed 13 h postoperatively.

Discussion

Impaired RV function is associated with a poor outcome in the surgical and nonsurgical settings. 1,4 The mortality of patients with combined arterial hypotension and severe RV dysfunction after CPB (defined as RV-fractional area change < 35%) can reach 86%. 5

Adequate treatment of RV failure consists of different strategies. The main goal is to decrease RV afterload by using vasodilating agents. The use of intravenously applied vasodilators is limited, as they are not selective to the pulmonary circulation and often cause arterial hypotension. Therefore, the administration of selective pulmonary vasodilators such as inhaled nitric oxide and prostacyclin may be beneficial. 5,6 Inhaled prostacyclin seems to be the more favorable agent because of its lack of toxicity, ease of application, and reduced costs. 5 Iloprost is the stable carbacyclin derivative of prostacyclin and can be administered intermittently, as the hemodynamic effects of a single dose are sustained for approximately 60-120 min. 7 Although the plasma half-life time of intravenously administered iloprost is known (20-30 min), no pharmacokinetic data are available concerning the plasma half-life time and the bioavailability after administration of inhaled iloprost. 8

Similar to inhaled prostacyclin, inhaled iloprost causes a more pronounced increase in cardiac output and a
greater degree of PVR-reduction when compared with inhaled nitric oxide. Inhaled iloprost has been successfully used in the long-term therapy of pulmonary hypertension and in the testing of pulmonary vascular responsiveness. To our knowledge, only three reports are available concerning the use of inhaled iloprost during cardiac surgery, two of them in patients awaiting or having undergone heart transplantation.

In the present case, we used inhaled iloprost as part of a stepwise approach to prevent RV failure in a patient with severe pulmonary hypertension undergoing combined valve surgery and coronary artery bypass grafting.

Administration of inhaled iloprost before CPB showed that the substance acted as an effective pulmonary vasodilator in our patient. Despite a concomitant decrease in mean arterial pressure and systemic vascular resistance (SVR), iloprost led to a more pronounced reduction of pulmonary artery pressure and PVR, so that the PVR/SVR ratio was remarkably decreased before CPB. During reperfusion, iloprost was again administered. PVR and pulmonary artery pressure were significantly decreased when compared with the preoperative values. However, the PVR/SVR ratio was increased after CPB, which can be attributed to an increase of PVR due to CPB-induced pulmonary vascular injury and to a decrease in SVR. Reduction of SVR after CPB is a well-known phenomenon mainly caused by hemodilution and activation of inflammatory mechanisms by extracorporal circulation. The additional use of milrinone contributed to the decrease in SVR.

We used inhaled iloprost during weaning from CPB as an integral part of the therapy and not as a rescue medication. This is in contrast to other case reports, in which inhaled nitric oxide, prostacyclin, or iloprost were used after RV failure had already occurred. The most effective dose and the best time for the administration of iloprost are still unknown. We used a dose of iloprost that is within the range described in the literature, and we administered the second dose before starting the weaning from CPB. Thus, an effective RV unloading could be expected in the immediate post-CPB period. RV failure with the need for an excessive dosage of catecholamines or even for reinstitution of CPB could be avoided. Despite the use of positive inotropic substances and surgical correction of valvular disease, echocardiographic parameters indicated a significant impair-

### Table 1. Hemodynamic Data

<table>
<thead>
<tr>
<th>Preoperative*</th>
<th>After Anesthesia Induction</th>
<th>Chest Open</th>
<th>After 12.5 μg Inhaled Iloprost</th>
<th>Chest Open</th>
<th>Chest Closed</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP, mmHg</td>
<td>100</td>
<td>78</td>
<td>72</td>
<td>62</td>
<td>66</td>
</tr>
<tr>
<td>CVP, mmHg</td>
<td>10</td>
<td>15</td>
<td>11</td>
<td>8</td>
<td>13</td>
</tr>
<tr>
<td>MPAP, mmHg</td>
<td>65</td>
<td>43</td>
<td>42</td>
<td>21</td>
<td>33</td>
</tr>
<tr>
<td>PAOP, mmHg</td>
<td>45</td>
<td>30</td>
<td>23</td>
<td>14</td>
<td>17</td>
</tr>
<tr>
<td>TPG, mmHg</td>
<td>20</td>
<td>13</td>
<td>19</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td>HR, min⁻¹</td>
<td>80</td>
<td>60</td>
<td>77</td>
<td>66</td>
<td>87</td>
</tr>
<tr>
<td>CO, l/min</td>
<td>3.5</td>
<td>2.5</td>
<td>2.5</td>
<td>5.2</td>
<td>5.7</td>
</tr>
<tr>
<td>SV, ml</td>
<td>32</td>
<td>41</td>
<td>32</td>
<td>78</td>
<td>65</td>
</tr>
<tr>
<td>SVR, dyne · s · cm⁻⁵</td>
<td>2,057</td>
<td>2,016</td>
<td>1,952</td>
<td>830</td>
<td>743</td>
</tr>
<tr>
<td>PVR, dyne · s · cm⁻⁵</td>
<td>457</td>
<td>416</td>
<td>606</td>
<td>107</td>
<td>224</td>
</tr>
<tr>
<td>PVR/SVR ratio</td>
<td>0.22</td>
<td>0.21</td>
<td>0.31</td>
<td>0.13</td>
<td>0.30</td>
</tr>
<tr>
<td>Epinephrine, μg · kg⁻¹ · min⁻¹</td>
<td>0.07</td>
<td>0.07</td>
<td>0.07</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>Norepinephrine, μg · kg⁻¹ · min⁻¹</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>Nitroglycerin, μg · kg⁻¹ · min⁻¹</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
</tr>
</tbody>
</table>

* Data obtained by cardiac catheterization. † After 12.5 μg of inhaled iloprost.

CO = cardiac output; CPB = cardiopulmonary bypass; CVP = central venous pressure; HR = heart rate; MAP = mean arterial pressure; MPAP = mean pulmonary artery pressure; PAOP = pulmonary artery occlusion pressure; PVR = pulmonary vascular resistance; SV = stroke volume; SVR = systemic vascular resistance; TPG = transpulmonary gradient (MAP – PAOP).

### Table 2. Intraoperative Changes for Hemodynamic Data Obtained by Transesophageal Echocardiography

<table>
<thead>
<tr>
<th>Pre-CPB</th>
<th>Post-CPB†</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV-EDA, cm²</td>
<td>32.3</td>
</tr>
<tr>
<td>LV-ESA, cm²</td>
<td>24.0</td>
</tr>
<tr>
<td>LV-FAC, %</td>
<td>25.70</td>
</tr>
<tr>
<td>LV-FAC, %</td>
<td>118</td>
</tr>
<tr>
<td>LVFS, ml</td>
<td>63.3</td>
</tr>
<tr>
<td>LVF, %</td>
<td>46.36</td>
</tr>
<tr>
<td>LVIDD, cm</td>
<td>5.00</td>
</tr>
<tr>
<td>LVVIDS, cm</td>
<td>3.01</td>
</tr>
<tr>
<td>FS, %</td>
<td>39.80</td>
</tr>
<tr>
<td>RV-EDA, cm²</td>
<td>18.7</td>
</tr>
<tr>
<td>RV-ESA, cm²</td>
<td>15.3</td>
</tr>
<tr>
<td>RV-FAC, %</td>
<td>18.18</td>
</tr>
</tbody>
</table>

Mid-esophageal four-chamber view and the short axis of transgastric view were evaluated.

* Closed chest, before administration of iloprost. † Closed chest, after administration of 12.5 μg inhaled iloprost.
mentation of left ventricular function after CPB, most probably caused by severe myocardial stunning. Thus, it seems unlikely that improvement of RV function was caused solely by the surgical procedure.

References


